TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05125627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
Description: Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
Study: NCT03149380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based education
Description: The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Web-based education
Description: The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
Study: NCT03123562

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study: NCT02163447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) for infants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) for infants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-monthly dihydroartemisinin-piperaquine (DP) for infants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-monthly dihydroartemisinin-piperaquine (DP) for infants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Study: NCT03654053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo taken once nightly at bed time.
Study: NCT01601015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position.
Study: NCT02602431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-oral laser irradiation
Description: Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-oral laser irradiation
Description: Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Extra-oral placebo
Description: Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-oral Placebo
Description: Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
Study: NCT00642616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin
Description: Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin
Description: Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
Study: NCT01359540

Intervention type: DEVICE
Intervention: OMNI Apex Modular™ Hip Device

Intervention type: DEVICE
Intervention: OMNI Apex ARC™ Hip Device
Study: NCT03389334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
Study: NCT02345161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple FF/UMEC/VI
Description: The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FF/UMEC/VI
Description: The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol
Description: The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
Study: NCT01782053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture warning
Description: Warning contains picture proposed for each text statement by FDA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture warning
Description: Warning contains picture proposed for each text statement by FDA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT02345161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Budesonide/Formoterol combination
Description: The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
Study: NCT02937948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptative treatment plan
Description: Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Description: At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
Study: NCT03654053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg taken once nightly at bed time.
Study: NCT03426657

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + RT
Description: Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
Study: NCT00663234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
Study: NCT03821675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation - Active
Description: Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical Stimulation - Sham
Description: Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
Study: NCT00594035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Sealant System
Study: NCT02345161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
Study: NCT00594035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care: devices intended to provide a watertight closure
Study: NCT01206387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone Spray 0.25%
Description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: Placebo administered to affected area twice a day for 28 days
Study: NCT02873585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary intraoral tomosynthesis
Description: Bitewing radiographs using a stationary intraoral tomosynthesis unit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard conventional bitewing radiography
Description: Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
Study: NCT03269552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study: NCT04201522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnic hyperpnoea intervention
Description: Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
Study: NCT03940573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse Insert
Description: Rectal Control System.
Study: NCT03269552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04174014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre
Description: PEEP increment and decrement
Study: NCT00588952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine and Placebo
Description: Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
Study: NCT04134858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The nurse-led health coaching program
Description: The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
Study: NCT01668433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regimens (Primaquine, Methylene blue)
Description: Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimens (Primaquine, Methylene blue)
Description: Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
Study: NCT00806624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin tablets
Description: Warfarin tablets taken once daily for up to 3 months
Study: NCT01403389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: 1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
Study: NCT01918293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART ARM
Description: The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
Study: NCT01508143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Description: Misoprostol 400 micrograms each 6 hours for 8 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 800 micrograms
Description: Misoprostol 800 micrograms each 12 hours for 4 doses
Study: NCT04332692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography
Description: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study: NCT03185676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilberry
Description: A bilberry based probiotic beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: beverage without bilberries or probiotics
Description: A control beverage without bilberries or probiotics
Study: NCT01403129

Intervention type: PROCEDURE
Intervention: Artemis Ultrasound Exam
Description: Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
Study: NCT02426918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 IV
Description: Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 IV
Description: Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
Study: NCT02346578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Study: NCT01520831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study: NCT00694538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Laser therapy
Description: Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Laser therapy
Description: Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
Study: NCT02426918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Oral
Description: Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Oral
Description: Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linezolid
Description: Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450 Oral Placebo
Description: Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Debio 1450 Oral Placebo
Description: Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Placebo
Description: Linezolid placebo will be supplied as film-coated compressed tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Placebo
Description: Linezolid placebo will be supplied as film-coated compressed tablets.
Study: NCT01403129

Intervention type: PROCEDURE
Intervention: Artemis Ultrasound Exam
Description: Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.

Intervention type: PROCEDURE
Intervention: Artemis Ultrasound Exam
Description: Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT) Exam
Description: OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT) Exam
Description: OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
Study: NCT02426918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin IV
Description: Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
Study: NCT02164435

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.